Genetics of Parkinson's disease by Gasser, Thomas
arkinson’s disease (PD) is a common neurode-
generative disorder,characterized clinically by the symp-
toms of akinesia (slowness and poverty of movements),
muscular rigidity,rest tremor,and disturbance of postural
reflexes.The pathological substrate is a neuronal loss pre-
dominantly of dopaminergic neurons of the substantia
nigra,in the presence of characteristic eosinophilic inclu-
sions,the Lewy bodies.The cause of most cases of PD is
still unknown,but both genetic and environmental fac-
tors are thought to contribute to the development of the
disease.
Genetic contributions to the etiology of PD were impli-
cated in early descriptions of the disease.
1 Later, the
importance of genetic factors was thought to be low due
to twin studies,which produced low concordance rates.
2,3
However,in more recent years,interest in the genetics of
PD has surged,as a consequence of the identification of
several monogenically inherited forms of the disease.The
mapping and cloning of an increasing number of disease
genes in these families has provided new insights into the
pathogenesis of the disorder (Table I).
4-13
Autosomal-dominant forms of PD
Monogenic forms of PD with autosomal-dominant inher-
itance appear to be extremely rare. Nevertheless, the
identification of disease-causing mutations has had a
major impact on our understanding of the pathogenesis
of PD.
PARK1
α-Synuclein was the first PD gene to be identified as caus-
ing autosomal-dominant parkinsonism in a large Italian-
American family (Contursi kindred).The clinical picture
was reported to be consistent with typical L-dopa–respon-
sive PD with Lewy body pathology,but with an unusually
early onset (mean 44 years) and rapid disease progression.
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The etiology of most cases of Parkinson’s disease (PD)
remains unknown. In recent years, however, research has
successfully focused on genetic factors contributing to
the degeneration of dopaminergic neurons. Causative
mutations have been identified in several monogenically
inherited forms of the disease. Although these genetic
forms of PD are usually rare, the gene discoveries are
likely to identify molecular pathways that are also rele-
vant in the sporadic disorder. These studies have led to
the identification of (i) the central role of  -synuclein
aggregation, secondary to either point mutations or an
amplification of the  -synuclein gene; and (ii) the rele-
vance of defects in the proteasomal protein degradation
pathway in the molecular pathogenesis of recessive
parkin-linked forms of PD. The recent discoveries of two
additional recessive forms associated with mutations in
the genes DJ-1 and PINK1 have brought the mitochon-
drial energy metabolism and the cell’s defence against
toxic free radicals into the focus of research. 
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(e-mail: thomas.gasser@med.uni-tuebingen.de)found in this and several (probably related) Greek fami-
lies.
4Two additional point mutations,A30P in a German
family
14 and E46K,
15 were identified later.
Although point mutations in the α-synuclein gene appear
to be a very rare cause of PD,
16,17 this finding was of great
importance because α-synuclein was subsequently iden-
tified as the principle component of the Lewy body,
which is also the pathological hallmark of typical spo-
radic PD.Consequently,the pathological aggregation of
α-synuclein is thought to play a central role in the mole-
cular pathogenesis of PD.This was further substantiated
by the recent finding of a triplication of a 2-Mb genomic
region containing the α-synuclein gene in a large auto-
somal-dominant family with PD.
7This genomic aberra-
tion leads to an overexpression of the intact α-synuclein
gene,indicating the susceptibility of neurons to an over-
load with this amyloidogenic protein.Interestingly,sev-
eral affected members of this kindred, as well as later
reported individuals with an A53T
18 and E46K point
mutation
15 had prominent dementia and pathological
findings consistent with Lewy body dementia,support-
ing the close relationship of this disease entity with PD.
A possible role of α-synuclein gene variants has also
been analyzed in sporadic PD.Some,but not all,studies
found a polymorphic dinucleotide repeat polymorphism
(NACP-Rep1) located about 4 kb upstream of the tran-
scriptional start site of the gene to be associated with spo-
radic PD.This variant may influence α-synuclein tran-
scriptional regulation and expression levels,as suggested
by CAT (chloramphenicol acetyltransferase) reporter
gene assays,
19,20 again suggesting that overexpression of
α-synuclein and subsequent aggregation may be a crucial
event in the pathogenesis of PD.
PARK3
Another autosomal-dominant locus has been described
(PARK3),located on chromosomal region 2p13,in a sub-
set of families with typical PD and Lewy body pathology.
6
Clinical features resemble those of sporadic PD including
a similar mean age of onset (59 years in these families).
The disease gene has not yet been identified.However,in
two independent genome-wide linkage analyses in sib-
pairs,significant association between age at onset of PD
and this gene locus was shown with maximum multipoint
LOD scores of 2.08 and 3.4,respectively,
21,22 suggesting that
the PARK3 gene may actually be a disease-modifying
locus rather than a true disease gene, similar to the
apolipoprotein E locus in Alzheimer’s disease.
PARK5: parkinsonism associated with mutations in the
gene for UCH-L1
A missense change in the gene for ubiquitin C-terminal
hydrolase 1 (UCH-L1) has been identified in two affected
members of a small family with PD,based on a candidate
gene–sequencing approach.
8 No other families have been
identified with disease-causing mutations,but a common
polymorphism in this gene (S18Y) was found to be pro-
tective in several association studies,including one meta-
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Table I. Genetically defined forms of Parkinson’s disease and parkinsonism. LB, Lewy body.
Locus/gene Inheritance Age of onset (years) Pathology Map position Gene Reference
PARK1 Dominant 40-50 Nigral degeneration with LBs 4q21 α-Synuclein 4
PARK2 Recessive 20-30 Nigral degeneration without LBs 6q25 Parkin 5
PARK3 Dominant 60-70 Nigral degeneration with LBs,  2p13 ? 6
plaques, and tangles in some
PARK4 Dominant 30-40 Nigral degeneration with LBs,  4q21 α-Synuclein 7
vacuoles in neurons of the hippocampus (triplication)
PARK5 Dominant ~50 Unknown 4p14 Ubiquitin   8
C-terminal
hydrolase L1
PARK6 Recessive ~40 Unknown 1p35-37 PINK-1 9
PARK7 Recessive ~40 Unknown 1p38 DJ-1 10
PARK8 Dominant ~50 Degeneration of dopaminergic  12cen ? 11
neurons without specific inclusions
PARK10 ? 50-60 Unknown 1p32 ? 12
PARK11 ? Late-onset Unknown 2q36 ? 13analysis.
23The precise role of this gene in the pathogenesis
of PD remains to be elucidated.
PARK8
This locus was first identified in a large Japanese family
(Samigahara family) with autosomal-dominant parkin-
sonism and linked to chromosome 12q.
11 The 
clinical phenotype showed typical PD with good response
to L-dopa and mean age at onset of 51 years.
Neuropathologically,four affected members showed non-
specific neuronal degeneration in the substantia nigra,but
no Lewy body formation.At least 2 out of 21 families of
European ancestry also showed significant linkage within
this locus.
24 Interestingly,in one of these families,various
pathologies have been found,including brain-stem Lewy
body disease,diffuse Lewy body disease,tau aggregation,
and nigral degeneration without distinctive inclusions,indi-
cating that mutations in this gene may be associated with
a relatively wide range of pathologies.
Autosomal-recessive forms of parkinsonism
Monogenic forms of recessive parkinsonism caused by
mutations in parkin (PARK2), PINK-1 (PARK6), and
DJ-1 (PARK7) represent an important cause of early-
onset parkinsonism (onset before 40 years of age).The
clinical phenotype of early-onset parkinsonism is often
characterized by dystonia at onset,hyperreflexia,early
complications on L-dopa treatment, and slow disease
progression.
PARK2:parkinsonism caused by mutations in the parkin
gene
Autosomal-recessive juvenile parkinsonism (AR-JP) was
first recognized in Japanese patients with an early-onset
form of PD (onset usually in the second or third decade)
and mapped to chromosome 6.
25 Mutations have been
identified in a large gene in this region called parkin.
5
Mutations in the parkin gene account for 50% of famil-
ial and about 15% of sporadic European PD patients
with onset before the age of 45 years.
26,27The proportion
of parkin mutations is clearly a function of the age at
onset (82% before age 20, but rare over the age of 55
years).
26,28 Different parkin mutations are known,includ-
ing quantitative alterations like exon deletions and dupli-
cations and point mutations.
In a study comparing parkin mutation carriers and non-
carriers of parkin mutations in a cohort with early-onset
parkinsonism,those with a mutation tended to have ear-
lier and more symmetrical onset,slower progression of the
disease, and greater response to L-dopa despite lower
doses.Lower-limb dystonia at disease onset occurs in about
a third of patients,but this feature does not appear to be
specific to parkin-related disease,and is more correlated
with the age at onset than with genetic status.
29 Functional
neuroimaging in parkin-linked parkinsonism showed
reduced uptake of dopamine tracer bilaterally in the puta-
men and caudate nucleus,in contrast to the initially uni-
lateral reduction in dopa uptake of sporadic PD
patients.
30,31 Psychiatric abnormalities have been recognized
in PD patients with parkin mutations.
32 Phenotype–geno-
type studies indicate that the type of mutation may influ-
ence the clinical phenotype to a certain degree:patients
with at least one missense mutation showed a faster pro-
gression of the disease with a higher Unified Parkinson’s
Disease Rating Scale (UPDRS) motor score than carriers
of truncating mutations.Missense mutations in functional
domains of the parkin gene resulted in earlier onset.
29
It remains unresolved whether parkin mutations also
represent a susceptibility factor for late-onset PD.
Heterozygous mutations are found in up to 6% in this
group,
33 but a recent study also detected known sequence
variants associated with parkinsonism in more than 3%
of healthy elderly individuals.
34 On the other hand,clin-
ically asymptomatic individuals with heterozygous parkin
mutations showed mildly reduced uptake of fluorodopa
in the basal ganglia,
35 indicating a possible “first hit”to
the nigrostriatal system.
As mutations of the parkin gene cause parkinsonism,in
all likelihood,by a loss-of-function mechanism,the study
of the normal function of parkin should provide insight
into the molecular pathogenesis of the disorder.Several
groups have now shown that parkin,a protein that has
been found in the cytosole,but also associated with mem-
branes,functions in the cellular ubiquitination/protein
degradation pathway as a ubiquitin ligase (Figure 1).
36-38
It is therefore conceivable that the loss of parkin func-
tion may lead to the accumulation of a nonubiquitinated
substrate,which is deleterious to the dopaminergic cell,
but, due to its nonubiquitinated nature, does not form
typical Lewy bodies.Several proteins have been shown
to interact with parkin and could possibly be its relevant
partner with regard to neurodegeneration:an O-glyco-
sylated form of α-synuclein
39;a protein associated with
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37;a transmembrane protein,
called the pael receptor
40; and synphillin-1.
41 However,
other pathogenetic mechanisms could also be important.
Recently, it has been shown that, in parkin knockout
mice,a number of genes related to the oxidative metab-
olism in mitochondria are downregulated. Oxidative
damage and dysfunction of components of the mito-
chondrial respiratory chain could be demonstrated,
implicating this pathway in the pathogenesis of PD.
42
PARK6: parkinsonism caused by mutations in the gene
for PINK1
Very recently,mutations in the gene for PINK1 (PTEN-
induced kinase 1) have been found to cause another
autosomal-recessive variant of early-onset PD,
39 PARK6,
which has previously been mapped to chromosomal
region 1p36.
43Two homozygous mutations affecting the
PINK1 kinase domain were identified in three consan-
guineous PARK6 families:a truncating nonsense muta-
tion and a missense mutation at a highly conserved
amino acid.Cell culture studies suggested that PINK1 is
a mitochondrially located protein and may exert a pro-
tective effect on the cell upon oxidative stress,which is
abrogated by the mutations.
9As in families with parkin
mutations, PINK1-associated parkinsonism is of early
onset and takes a relatively benign cause.
PARK7: parkinsonism caused by mutations in the gene
for DJ-1
Another recessive locus was mapped to chromosome 1
in a consanguineous Italian family.
44These patients had
disease onset in their mid-thirties with L-dopa respon-
siveness,slow progression,and focal dystonic symptoms,
such as blepharospasm.Pathogenic mutations were iden-
tified in the gene for DJ-1.
10A missense mutation result-
ing in the substitution of a highly conserved leucine for a
proline at position 166 (L166P mutation) and a large
homozygous deletion of several exons (exons 1 to 5)
were detected in an Italian and a Dutch family,respec-
tively.Both DJ-1 mutations are thought to lead to a loss
of function:the deletion leads to a complete loss of the
protein, the L166P mutation is thought to impair the
dimerization and the tertiary structure of DJ-1,resulting
in a functionally inactive monomeric form of the pro-
tein.
45,46The function of DJ-1 is still largely unknown,but
there is some evidence that the protein may play a role
in the cellular response to oxidative stress, which may
render dopaminergic neurons particularly vulnerable.
This oxidative stress response may be caused by interac-
tions of DJ-1 with other proteins like protein inhibitor of
activated STAT (signal transducer and activator of tran-
scription) (PIASxα),DJ-1-binding protein (DJBP),and
the RNA-binding protein complex;DJ-1 may also regu-
late the dismutation of peroxides.
47,48
The prevalence of pathogenic DJ-1 mutations in young-
onset PD patients is certainly much lower than that of
parkin,and is estimated to be less than 1%.
49,50 No path-
ogenic mutation was found in 190 pathologically proven
patients with later onset PD.
Identification of susceptibility alleles 
in nonmendelian PD
Although significant progress has been made in families
with mendelian subtypes of PD,it must be remembered
that PD,in the great majority of cases,is a sporadic dis-
order.The type and the extent of a genetic contribution
to nonmendelian PD is still controversial.A population-
based,case-control study indicates that the relative risk
for first-degree family members of PD patients is
increased only in the order of 2 to 3.
51
Most attempts to identify the susceptibility genes in spo-
radic PD,have followed a candidate gene approach.On
the basis of pathological, pathobiochemical, and epi-
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Figure 1. Parkin and its function in the ubiquitin-proteasome system (UPS).
Parkin functions as a ubiquitin ligase, by adding ubiquitin, a small
signal polypeptide, to target proteins. The polyubiquitinated pro-
tein is directed to the proteasome, a multi-subunit protease that
degrades the target protein. Ubiquitin is recycled by ubiquitin C-
terminal hydrolase L-1 (UCH-L1). Parkin mutations may lead to
a failure of the UPS, to accumulation of unwanted proteins, and
consequently to cell damage.
Reproduced with permission from reference 38: Gasser T. Parkin and its
role in Parkinson's disease. In: Ebadi M, Pfeiffer R, eds. Parkinson's Disease.








Accumulationdemiological findings,hypotheses on the etiology of PD
can be generated and genetic polymorphisms within—or
closely linked to—genes that are thought to be involved
in these pathways have been examined.Unfortunately,
no consistent findings have emerged so far.
Major international efforts therefore focus on the exam-
ination of large cohorts of affected sibpairs or small
nuclear families with the methods of nonparametric link-
age analysis,using whole-genome approaches.Several of
these studies have been published.
12,52-54Their results indi-
cate that the contribution of any individual locus to PD
is likely to be modest,as linkage peaks in these studies
generally were rather low and most of them not repro-
duced in other studies (with the exception of a locus on
chromosome 5 and one on the X chromosome).This is
most likely due to the enormous locus heterogeneity in
late-onset PD.Therefore,international collaborations and
pooling large patient resources will be necessary to nar-
row down linkage regions and conduct more advanced
studies,such has high-resolution linkage disequilibrium
(LD) mapping,which will eventually result in the identi-
fication of the genetic variants responsible.
Conclusion
The genetic findings in rare inherited forms of PD have
greatly contributed to our understanding of the clinical,
neuropathological,and genetic heterogeneity of PD.The
variability of clinical features,such as age at onset,occur-
rence of dementia,or other associated features,that has
been found within single families suggests that a single
genetic cause (the pathogenic mutation in a given fam-
ily) can lead to a spectrum of clinical manifestations.On
the other hand,individuals with different genetic defects
and different neuropathologies (eg,some of those with
mutations in the PARK1 and PARK2 genes) may be clin-
ically indistinguishable from each other and fulfill all
presently accepted criteria of idiopathic PD.It is there-
fore apparent that a new genetic classification of PD is
about to emerge,which is only partially congruent with
the classic clinical and pathological classification.
There is currently convincing evidence that genetic fac-
tors play an important role in the etiology of at least a
subset of patients with PD.Only a small percentage of
cases with dominant or recessive inheritance can prob-
ably be explained by mutations in the genes that have
been identified so far (the genes for α-synuclein,ubiqui-
tin carboxy-terminal hydrolase L1, DJ-1, PINK1, and
parkin) or by mutations in the as yet unidentified genes
on chromosome 1, 2p, and 12. However, the study of
wildtype and mutated gene products will provide impor-
tant insights into the molecular pathogenesis of nigral
degeneration and Lewy body formation.Further intense
efforts are still needed to unravel the full spectrum of eti-
ological factors leading to the common sporadic form of
this neurodegenerative disorder. ❏
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Genética de la enfermedad de Parkinson
Se desconoce la etiología de la mayoría de los casos
de enfermedad de Parkinson (EP). En años recien-
tes, sin embargo, la investigación se ha centrado
exitosamente en los factores genéticos que contri-
buyen a la degeneración de las neuronas dopami-
nérgicas. Se han identificado mutaciones causales
en algunas formas monogénicas heredadas de la
enfermedad. Aunque estas formas genéticas de la
EP son habitualmente raras, es posible que los des-
cubrimientos genéticos identifiquen vías molecula-
res que también sean importantes en la enferme-
dad esporádica. Estos estudios han conducido a la
identificación de: (i) el papel central de la agrega-
ción de  -sinucleína, la que puede ser secundaria a
mutaciones de puntos del gen de  -sinucleína o a
una sobre-expresión de éste y (ii) la importancia de
los defectos en la vía de degradación de la proteína
proteasómica en la patogénesis molecular de las
formas recesivas ligadas al gen parkin de la EP. Los
descubrimientos recientes de dos formas recesivas
adicionales asociadas con mutaciones en los genes
DJ-1 y PINK1 han puesto el foco de atención de la
investigación en el metabolismo energético mito-
condrial y en la defensa de la célula contra los radi-
cales libres tóxicos.
Génétique de la maladie de Parkinson
L’étiologie de la plupart des cas de maladie de
Parkinson (MP) reste inconnue. Ces dernières
années, cependant, la recherche s’est axée avec
succès sur les facteurs génétiques impliqués dans la
dégénérescence des neurones dopaminergiques.
Des mutations causales ont été identifiées dans plu-
sieurs formes héréditaires monogéniques de la
maladie. Bien que ces formes génétiques de MP
soient habituellement rares, la découverte de ces
gènes permettra probablement l’identification de
voies moléculaires qui sont aussi mises en jeu dans
la forme sporadique de la maladie. Ces études ont
conduit à la mise en évidence (1) du rôle central de
l’agrégation de l’ -synucléine, secondaire à des
mutations ponctuelles ou à la surexpression du
gène de l’ -synucléine ; et (2) de la pertinence des
défauts de la voie de dégradation des protéines
protéosomales dans la pathogenèse moléculaire
des formes récessives de MP liées au gène parkin.
La découverte récente de deux formes récessives
supplémentaires liées aux mutations des gènes 
DJ-1 et PINK1 fait du métabolisme énergétique
mitochondrial et de la défense cellulaire contre les
radicaux libres toxiques un axe privilégié de la
recherche.
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